Cancer - information and treatment Cancer - information and treatment.
Nanomicellesin cancer cancer treatment
-
Upload
sasikarn-sripetthong -
Category
Health & Medicine
-
view
110 -
download
1
Transcript of Nanomicellesin cancer cancer treatment
![Page 1: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/1.jpg)
1
LOGO
Presented BySasikarn Sripetthong
Student ID 5610730014
Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University
Nanomicelles in Cancer treatment
![Page 2: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/2.jpg)
2
Contents
2
Conclusion3
Introduction1
Example of publications
• Strategies to enhance anticancer activityby using drug delivery system• Nanomicelles
![Page 3: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/3.jpg)
3
Figure 1 Cancer incidence Worldwide
http://www.cancerresearchuk.org
![Page 4: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/4.jpg)
4
http://www.who.int/mediacentre/factsheets/f
Cancer
![Page 5: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/5.jpg)
Alkylating agents nitrogen mustards thiotepa, busulfan nitrosoureas, mitomycin procarbazine, dacarbazine
Taxanes paclitaxel, docetaxel nab-paclitaxel
Topoisomerase II inhibitors etoposide
Platinum Complexes cisplatin, carboplatin oxaliplatin
Anthracyclines doxorubicin, daunorubicin idarubicin, mitoxantrone
Antimetabolites methotrexate purine antagonists pyrimidine antagonists
Tubulin interactive agents vincristine, vinblastine
Miscellaneous agents bleomycin asparaginase hydroxyurea
Chemotherapy Classes
Licciardi, M., E. F. Craparo, et al. (2008)
![Page 6: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/6.jpg)
6
Limitations of Chemotherapy drugs
Figure 2 Erythema and dysthesia on back of hands accompanied by sublingual inflammation on several digits after 4 months of chemotherapy with paclitaxel.
Paclitaxel
Licciardi, M., E. F. Craparo, et al. (2008)
![Page 7: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/7.jpg)
7
To overcome the limitation by using nanoparticles
Nanoparticles – any particles that have sized between 1 and 1000 nanometers (in terms of diameter)
Okuda, T., S. Kawakami, et al. (2009)
Suitable size 10-100nm
![Page 8: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/8.jpg)
8
Advantages of Nanoparticles
Protects drugs from being degraded in the body before they reach their target.
Allows for better control distribution of drugs to the tissue, making it easier for oncologists to assess the efficiency of treatment.
Enhances the absorption of drugs into tumors and cancer cells.
Prevent drugs from interacting with normal cells, thus avoiding side effects.
Zhang, Y., Y. Huang, et al. (2014)
![Page 9: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/9.jpg)
9
Ahuja, N., Katare, O. P., et al. J. of Pharmaceutics and Biopharmaceutics. 2007, 65,
26-38.
Liposome
Types of Nanoparticles
Nanomicelles
Micelles
Dendrimers
Nanospheres
Nanocapsules
Fullerenes and nanotubes
![Page 10: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/10.jpg)
10
Micelles
Figure 3 Micelles formation Licciardi, M., E. F. Craparo, et al. (2008)
![Page 11: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/11.jpg)
11
Advantages of nanomicelles utilization in anticancer drug delivery
- biocompatible material (copolymer)
- versatility to encapsulate a wide rage of therapeutic drugs
- stable to dilution within blood stream
Licciardi, M., E. F. Craparo, et al. (2008)
![Page 12: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/12.jpg)
![Page 13: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/13.jpg)
Figure 3 Drug loaded polymeric micelle
Licciardi, M., E. F. Craparo, et al. (2008)
![Page 14: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/14.jpg)
14
![Page 15: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/15.jpg)
15
Selectivity of micelles in drugs delivery for cancer treatment
Chen, Y.-C., C.-L. Lo, et al. (2013)
![Page 16: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/16.jpg)
16
![Page 17: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/17.jpg)
17
Examples of publications in nanomicelles anticancer drug delivery
![Page 18: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/18.jpg)
18
OH
O
O
O
HOO
OO
HOO
O
OH
NHO
O
EO PO EO
P-123 :EO20PO70EO20
P-127 :EO100PO65EO100
Zhang, W., Y. Shi, et al. (2011).
CMC = 0.0028 %
![Page 19: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/19.jpg)
19
Figure 4 % cell viability of Taxol and PF-PTX against B16F10 cells.
Zhang, W., Y. Shi, et al. (2011).
![Page 20: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/20.jpg)
20
Sample IC50(ng/mL)
ToxolPF-PTX micelles
65.9 ± 3.527.8 ± 6.8
Table 1 The IC50 values of Toxol and PF-PTX micelles and the control
Zhang, W., Y. Shi, et al. (2011).
![Page 21: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/21.jpg)
21
Figure 5 Cellular internalization of PF-FITC in B16F10 pulmonary metastatic melanoma cells.
Zhang, W., Y. Shi, et al. (2011).
![Page 22: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/22.jpg)
22
Figure 6 Antitumor efficacy of different PTX formulations on the survival of subcutaneous B16F10 tumor-bearing mice (n=8).
Zhang, W., Y. Shi, et al. (2011).
(10 mg/Kg)
14.5
2224.5 31.5
![Page 23: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/23.jpg)
23
Figure 7 Images of lungs excised from the tumor-bearing mice on day 10 after three consecutive treatments and photographs of the hematoxylin and eosin-stained tissue sections processed from the excised lungs.
Zhang, W., Y. Shi, et al. (2011).
![Page 24: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/24.jpg)
24
O OP
O
O H O-O N
H(OCHCH2)45OCH
O
NH4
Paclitaxel
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (mPEG2000-DSPE)
17-AAG
Katragadda, U., W. Fan, et al. (2013).
O
O
O
O
(CH2CH2O)nH
CH3
CH3
CH3
CH3 CH3 CH3
CH3
H3C D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)
![Page 25: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/25.jpg)
25
11 nm
Figure 8 The hydrodynamic diameter of the dual drug-loaded micelles
stable at both 4 °C and 37 °C for at least 4 weeks
![Page 26: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/26.jpg)
26
Figure 9 Circulation and disposition characteristic of the drug load micelles.
Katragadda, U., W. Fan, et al. (2013).
![Page 27: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/27.jpg)
27
Figure 10 The antitumor efficacy by paxlitaxel/17 AAG in human ovariean tumor mouses modell.
Katragadda, U., W. Fan, et al. (2013).
Non-treated group (n=6)
(n=6)(n=6)
AB
C
B and C were administration by IV at 0,7 and 14 days
![Page 28: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/28.jpg)
The pH of cancer is lower than the normal tissue.
pH in the tumor mass is about 6.5-7.2 and the surrounding tissue is about pH 7.4.
The micro-environment of a tumor is acidic because insufficient oxygen in tumors leads to hypoxia and causes production of lactic acid.
Pathological properties of cancer
![Page 29: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/29.jpg)
Vasculature and temperature of tumor
Figure 11 Possible mechanism explaining why tumors get hotter than surrounding normal tissues
![Page 30: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/30.jpg)
30
OH
O
HO
HOO
OO
HOO
O
OH
NH
O
O
O
O
H
pH- and temperature-responsive polymeric micelles
mPEG-b-P(HPMA-Lac-co-His)Doxorubicin
Chen, Y.-C., L.-C. Liao, et al. (2012).
CMC = 1.25×10-2
mPEG-b-PLACMC = 3.65×10-2
![Page 31: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/31.jpg)
31
Figure 12 Transmission electron micrographs of Dox-micelle.
DOX-micelle optimal size = 50.7 nm and PDI = 0.12
DOX- micelle
![Page 32: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/32.jpg)
32
![Page 33: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/33.jpg)
33
Figure 13 Effects of pH on doxorubicin release from micell in vitro at 37 °C a dual responsive micelle
Chen, Y.-C., L.-C. Liao, et al. (2012).
![Page 34: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/34.jpg)
34
Figure 14 In vitro release of dual responsive micelle
(37 °C) (25 °C)
![Page 35: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/35.jpg)
35
Cell lines IC50(µg/mL)
Dox Dox-Micelle
24 h 72 h 24 h 72 h
HelaMCF-7
ZR-75-1H661
8.224.930.550.34
4.261.950.530.31
2.972.270.550.20
1.580.830.300.28
Table2 IC50 values of free doxorubicin and Dox-loaded micelle for cancer cells.
Chen, Y.-C., L.-C. Liao, et al. (2012).
![Page 36: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/36.jpg)
36
Figure 15 Optical fluorescence imaging in vivo of HeLa tumors xenografted into nude mice and treated with Cy5.5-Dox-micelle.
Chen, Y.-C., L.-C. Liao, et al. (2012).
![Page 37: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/37.jpg)
37
Figure 16. Folate-mediated delivery of therapeutic agents to folate receptor- positive cancer cells.
![Page 38: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/38.jpg)
38
Figure 17 Design of polymeric micelles and the rationale for active drug delivery.
![Page 39: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/39.jpg)
39
Figure 18 Chemical structures of folate-poly(ethylene glycol)-Poly (aspartate- hydrazone-adriamycin) and methoxy-poly(ethylene glycol)-
poly(aspartate-hydrazone-adriamycin) block copolymers.
Folate-Conjugated pH-Sensitive Polymeric Micelle
![Page 40: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/40.jpg)
40
Sample Size (nm)
FMA
MA
91.29
64.21
Table 3 Particle Size of the Folate conjugate micelles and micelles.
FMA=Folate-poly(ethylene glycol)-Poly(aspartate-hydrazone-adriamycin) micelleMA= methoxy-poly(ethylene glycol)-poly(aspartate-hydrazone-adriamycin) miclle
![Page 41: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/41.jpg)
41
Sample ExposureTime (h)
IC50
µg/mL±SDCellular
Uptake (%)
ADRFMA MA
ADRFMA MA
333
242424
0.069±0.0140.172±0.017
N.D.
0.035±0.0110.041±0.0120.263±0.013
100.0092.5140.20
100.0098.9582.05
Table 4 Time-Dependent Increase in Cytotoxicity and Cellular Uptake of the Micelles (n=8).
![Page 42: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/42.jpg)
42
Figure 19 Tumor size change
![Page 43: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/43.jpg)
43
Figure 20 Body weight change
![Page 44: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/44.jpg)
44
Conclusion
Nanomicelles is a successful drug delivery system to improve drug to the target site Utilization nanomicelles for anticancer should have size to between 10-100 nmpH sensitive and temperature sensitive nanomicelles could improve drug internalisation to cancer cellPolymer conjugated with targeting agent could improve tumor specific drug delivery Lower toxicity to the normal cell can be obtained.
![Page 45: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/45.jpg)
Acknowledgment
Assist.Prof.Dr. Chitchamai Ovatlarnporn
![Page 46: Nanomicellesin cancer cancer treatment](https://reader031.fdocuments.in/reader031/viewer/2022013111/55b21726bb61eba20b8b4779/html5/thumbnails/46.jpg)
46
LOGO